CGA
NVO

Channing Global Advisors’s Novo Nordisk NVO Stock Holding History

Channing Global Advisors’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.06M Buy
42,883
+11,698
+38% +$503K 1.06% 20
2026
Q1 		$1.15M Sell
31,185
-341
-1% -$16.2K 0.67% 25
2025
Q4 		$1.6M Buy
31,526
+7,650
+32% +$391K 1.03% 22
2025
Q3 		$1.32M Buy
23,876
+8,648
+57% +$506K 0.92% 23
2025
Q2 		$1.05M Buy
15,228
+4,530
+42% +$308K 0.68% 26
2025
Q1 		$743K Buy
10,698
+6,581
+160% +$544K 0.51% 28
2024
Q4 		$354K Buy
+4,117
New +$445K 0.24% 38
2023
Q3 		– Sell
-598
Closed -$48.4K – 49
2023
Q2 		$48.4K Sell
598
-604
-50% -$49.3K 0.05% 46
2023
Q1 		$95.6K Hold
1,202
– – 0.11% 43
2022
Q4 		$81.3K Buy
1,202
+736
+158% +$43.2K 0.09% 41
2022
Q3 		$23K Hold
466
– – 0.03% 41
2022
Q2 		$26K Hold
466
– – 0.03% 43
2022
Q1 		$26K Sell
466
-3,660
-89% -$188K 0.03% 40
2021
Q4 		$231K Buy
+4,126
New +$224K 0.22% 37

Other funds holding NVO

SRIM
Saratoga Research & Investment Management Saratoga, California $1.83B AUM 18.41% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
GA
GuoLine Advisory Singapore $1.07B AUM 26.27% 1-Year Est. Return
AIIMS
Analyst IMS Investment Management Services Tel-Aviv, Israel $4.3B AUM 37.33% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
QI
QV Investors Calgary, Alberta, Canada $1.3B AUM 31.14% 1-Year Est. Return
AA
ABC Arbitrage Paris, France $926M AUM 45.9% 1-Year Est. Return
GIM
Generate Investment Management Auckland, New Zealand $2.43B AUM 37.24% 1-Year Est. Return
CFB
Cullen/Frost Bankers San Antonio, Texas $10.1B AUM 29.18% 1-Year Est. Return

Channing Global Advisors's NVO Position: Q2 2026 in Review

Channing Global Advisors increased its Novo Nordisk (NVO) stake by 38% in Q2 2026, buying an estimated $503K and bringing the position to 42,883 shares worth $2.06M. The position accounts for 1.06% of the portfolio, ranked #20.

Channing Global Advisors first reported a position in NVO in Q4 2021 and has held it in 14 quarters since. 543 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Channing Global Advisors held 42,883 shares of Novo Nordisk worth $2.06M as of Q2 2026.
  • Channing Global Advisors bought 11,698 Novo Nordisk shares in Q2 2026, an estimated $503K.
  • Novo Nordisk made up 1.06% of Channing Global Advisors's portfolio in Q2 2026, its #20 holding.
  • Channing Global Advisors first reported a position in Novo Nordisk in Q4 2021 and has held it in 14 quarters since.
  • 543 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Channing Global Advisors's 13F filing for Q2 2026, filed 28 Jul 2026.